The 36-month beta value for ZNTL is at 1.70. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ZNTL is 61.38M, and currently, shorts hold a 19.06% of that float. The average trading volume for ZNTL on October 02, 2024 was 1.78M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ZNTL) stock’s latest price update
The stock of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has decreased by -2.99 when compared to last closing price of 3.68. Despite this, the company has experienced a -11.19% fall in its stock price over the last five trading sessions. zacks.com reported 2024-09-17 that ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
ZNTL’s Market Performance
Zentalis Pharmaceuticals Inc (ZNTL) has seen a -11.19% fall in stock performance for the week, with a 2.88% gain in the past month and a 0.00% plunge in the past quarter. The volatility ratio for the week is 6.18%, and the volatility levels for the past 30 days are at 9.49% for ZNTL. The simple moving average for the last 20 days is -0.97% for ZNTL stock, with a simple moving average of -63.42% for the last 200 days.
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $4 based on the research report published on August 12, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $5, previously predicting the price at $28. The rating they have provided for ZNTL stocks is “Neutral” according to the report published on June 20th, 2024.
ZNTL Trading at 0.88% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.27% of loss for the given period.
Volatility was left at 9.49%, however, over the last 30 days, the volatility rate increased by 6.18%, as shares surge +10.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.97% lower at present.
During the last 5 trading sessions, ZNTL fell by -11.19%, which changed the moving average for the period of 200-days by -76.47% in comparison to the 20-day moving average, which settled at $3.62. In addition, Zentalis Pharmaceuticals Inc saw -76.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Gallagher Cam, who sale 9,597 shares at the price of $11.98 back on May 31 ’24. After this action, Gallagher Cam now owns 633,680 shares of Zentalis Pharmaceuticals Inc, valued at $114,972 using the latest closing price.
HAUSMAN DIANA, the Chief Medical Officer of Zentalis Pharmaceuticals Inc, sale 3,356 shares at $12.62 during a trade that took place back on May 09 ’24, which means that HAUSMAN DIANA is holding 373,876 shares at $42,353 based on the most recent closing price.
Stock Fundamentals for ZNTL
Current profitability levels for the company are sitting at:
- -5.17 for the present operating margin
- 0.97 for the gross margin
The net margin for Zentalis Pharmaceuticals Inc stands at -4.56. The total capital return value is set at -0.52. Equity return is now at value -42.98, with -34.97 for asset returns.
Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.78. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -37.06.
Currently, EBITDA for the company is -252.55 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 6.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.59.
Conclusion
In conclusion, Zentalis Pharmaceuticals Inc (ZNTL) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
